How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

26,257 results for

Viral Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. End hepatitis by 2030: prevention, care and treatment of viral hepatitis in the African Region: framework for action, 2016-2020

End hepatitis by 2030: prevention, care and treatment of viral hepatitis in the African Region: framework for action, 2016-2020 End hepatitis by 2030: prevention, care and treatment of viral hepatitis in the African Region: framework for action, 2016-2020 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links End hepatitis by 2030: prevention, care and treatment of viral hepatitis (...) in the African Region: framework for action, 2016-2020 View/ Open View Statistics Altmetrics Share Citation World Health Organization. Regional Office for Africa . (‎2017)‎. End hepatitis by 2030: prevention, care and treatment of viral hepatitis in the African Region: framework for action, 2016-2020. World Health Organization. Regional Office for Africa. Description iv, 17 p. Other Language Versions Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World

2017 WHO

2. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. (PubMed)

Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Chronic infections with hepatitis B or C (HBV and HCV) are associated with adverse clinical outcomes and patient-reported outcomes (PROs). The aim is to compare PRO scores in patients with chronic HBV and HCV without advanced liver disease before and after suppression/clearance of their infection.Patients with HCV and HBV infection prior to initiation of antiviral (...) treatment and after viral suppression/eradication completed PRO questionnaires.We included 132 patients with HBV and 132 matched patients with HCV. Baseline PRO scores were significantly higher in patients with HBV in the domains of Physical Functioning, Role Physical, Bodily Pain, Social Functioning, and Role Emotional of SF-36, SF-6D utility, Emotional and Fatigue domains of CLDQ, Presenteeism and total Work Productivity Impairment of WPAI:SHP in comparison to patients with HCV by 5.8%-13.2% of a PRO

2019 Liver International

3. Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. (PubMed)

Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. Egypt ranks fifth for the burden of viral hepatitis worldwide. As part of Egypt's renewed national strategy for the elimination of viral hepatitis, surveillance for acute viral hepatitis (AVH) was re-established during 2014-2017 to describe the current (...) epidemiology and associated risk factors, and changes from surveillance conducted during 2001-2004.Patients with suspected AVH were enrolled, completed a questionnaire, and provided blood for testing for hepatitis viruses A (HAV), B (HBV), C (HCV), D, and E (HEV) infections by enzyme-linked immunosorbent assay. Odds ratios and Chi2 were used to detect differences between hepatitis types by patient characteristics and exposures. Newcombe-Wilson method was used to compare results between surveillance periods

Full Text available with Trip Pro

2019 BMC Infectious Diseases

4. Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017–2021

Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017–2021 Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017–2021 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017–2021 (...) View/ Open Rights View Statistics Altmetrics Share Abstract The Regional action plan for viral hepatitis 2017–2021 aims to encourage Member States to develop country-specific national hepatitis response plans based on the needs and priorities of affected people and communities, as well as on the capacity of the national health sector to address these needs. It prioritizes known effective interventions, promotes equitable access to hepatitis services and sets programmatic milestones for 2018

2017 WHO

5. Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease (PubMed)

Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease In Japan, the estimated number of chronic hepatitis B virus infections was 1.1 to 1.4 million, and that of chronic hepatitis C virus was 1.9 to 2.3 million in 2000. The mortality of hepatocellular carcinoma had been increasing and hit the peak at around 2002, which subsequently started to decrease. Japan has a national action plan for addressing viral hepatitis called Basic (...) B or C and on treatment, drug prices of nucleotide analogs, interferon (IFN) treatment, or IFN-free direct antiviral agents along with examination expenses should be covered by special programs for viral hepatitis. The national and local governments cover the amount in excess of 100 to 200 USD of the cost of treatment. The proportion of liver cancer with nonviral etiology has been increasing in Japan. For the screening and follow-up of patients with nonalcoholic fatty liver disease, we

Full Text available with Trip Pro

2017 Euroasian journal of hepato-gastroenterology

6. Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients. (PubMed)

Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients. We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C (HCV) dual-infected patients after anti-HCV therapy.A total of 192 HBV/HCV dual-infected patients who had received pegylated interferon treatment were recruited. The investigation outcomes included HBV DNA ≥2000 IU/mL, with or without alanine aminotransferase (ALT) ≥2 (...) -fold the upper limit of normal, and hepatitis B surface antigen (HBsAg) seroclearance.Four (2.1%) patients developed early HBV reactivation before the end of treatment. Fifty (26.6%) of the remained patients had an episode of HBV DNA ≥2000 IU/mL in a mean follow-up of 68.8 months. The risk was 4.6 per 100-person-year. Only 19 (10.1%) patients developed concomitant ALT flare with oral HBV antiviral therapy; the risk was 1.7 per 100-person-year. Despite HBV flare, 67 (34.9%) patients had a favorable

2018 Journal of Infectious Diseases

7. Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. (PubMed)

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. Hepatitis C virus (HCV) and hepatic dysfunction are associated with low total and free testosterone (TT and FT) and high sex hormone-binding globulin (SHBG). However, little is known about changes in testosterone following successful HCV treatment.We evaluated testosterone levels and the prevalence of low testosterone in a cohort of 327 men with chronic HCV infection (human immunodeficiency virus [HIV

2019 Clinical Infectious Diseases

8. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing? (PubMed)

Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing? Hepatitis C virus (HCV) antigen testing is less expensive than quantitative RT-PCR but has lower sensitivity for very low viral loads (VLVL; HCV RNA ≤3,000 IU/ml). Currently the benefits of antigen testing for screening are discussed, but data on prevalence and outcomes of persons with VLVL are scarce.We assessed prevalence and predictors of VLVL by logistic regression in treatment (...) -naïve participants in the Swiss Hepatitis C Cohort Study. We analyzed if the last viral load after VLVL was low, compared cirrhosis and mortality in persons with and without VLVL, and evaluated the number of samples with VLVL that were reactive by antigen testing.We included 2,533 treatment-naïve persons with available quantitative HCV RNA testing results. Overall, 133 persons (5.3%) had a VLVL. Age 18-40 years, female gender and HIV coinfection were associated with VLVL. Of 72 persons with a viral

2019 Clinical Infectious Diseases

9. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. (PubMed)

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Hepatitis B e antigen (HBeAg) is an important serological marker of hepatitis B virus (HBV) infection and is associated with higher levels of viraemia, increased risk of infectivity to others and increased risk of hepatocellular carcinoma. We analysed HBeAg status in a large cohort of adults and children enrolled in Cohort Studies of the Hepatitis B Research

2019 Journal of viral hepatitis

10. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. (PubMed)

The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. The hepatitis C virus (HCV) care cascade has changed dramatically following the introduction of direct-acting anti-virals (DAAs). Up-to-date estimates of the cascade are needed to monitor progress, identify key gaps and inform policy.To estimate the current and future HCV care cascade in the United States, nationally and in select

2019 Alimentary Pharmacology & Therapeutics

11. Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system. (PubMed)

Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system. Hepatitis B virus (HBV) remains a major global health problem with 257 million chronically infected individuals worldwide, of whom approximately 20 million are co-infected with hepatitis delta virus (HDV). Progress towards a better understanding of the complex interplay between these two viruses and development of novel therapies have been hampered by the scarcity of suitable cell (...) culture models that mimic the natural environment of the liver. Here, we established HBV and HBV/HDV co- and super-infections in self-assembling co-cultured primary human hepatocytes (SACC-PHHs) for up to 28 days in a 384 well format and highlight the suitability of this platform for high-throughput drug testing. We performed RNAseq at days 8 and 28 on SACC-PHHs either HBV mono- or HBV/HDV co-infected. Our transcriptomic analysis demonstrates that hepatocytes in SACC-PHHs maintain a mature hepatic

2019 Hepatology

12. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. (PubMed)

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. While acute changes in hepatic fibrosis are recognized shortly after achieving sustained virologic response (SVR) using direct acting antiviral therapies, long-term outcomes for the growing population of successfully treated patients with hepatitis C virus (HCV) remain uncertain. The aim of this study is to characterize long-term changes in fibrosis following SVR in patients (...) years.Fibrosis progression occurred in 4% of subjects while regression occurred in 7% and 89% were stable and did not differ by HIV coinfection. Fibrosis progression was associated with increased body mass index (BMI), hepatic steatosis, and smoking pack-years. In a multivariable logistic regression, HIV coinfection (p=0.009), lower steatosis score (p<0.05) and lower smoking pack-years (p=0.0007) were associated with a lower fibrosis score at last follow-up.We identify potentially important relationships

2019 Antiviral Therapy

13. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut

An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut 12-week grazoprevir/elbasvir is highly effective in hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of 8-week regimen for naïve patients with mild fibrosis is elusive.HCV-1b naïve patients with mild fibrosis were randomized to 8 (...) (n=41) or 12 (n=41) weeks of elbasvir/grazoprevir. The primary endpoint was SVR12 (HCV RNA < 12 IU/ml at post-treatment week-12).SVR12 was achieved by 87.8% (36/41) and 100% (41/41) in the full-analysis population and 90.0% (36/40) and 100% (41/41) in the per-protocol population in the 8-week and 12-week arms, respectively (all p=0.055). In the 8-week arm, a significantly lower SVR12 rate was observed among patients with a high viral loads (HVL,>1,500,000 IU/mL, 79% vs. 100%, p=0.042) and those

2019 EvidenceUpdates

14. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. (PubMed)

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) , -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.Lack of lipid, fibrosis, or HCC surveillance data.In a nationwide viral hepatitis cohort, lipophilic statins were associated with significantly reduced HCC incidence

2019 Annals of Internal Medicine

15. Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. (PubMed)

Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. As more countries worldwide develop national viral hepatitis strategies, it is important to ask whether context-specific factors affect their decision-making. This study aimed to determine whether country-level socioeconomic factors are associated with viral hepatitis programmes and policy responses across WHO Member (...) States (MS).WHO MS focal points completed a questionnaire on national viral hepatitis policies. This secondary analysis of data reported in the 2013 Global Policy Report on the Prevention and Control of Viral Hepatitis in WHO Member States used logistic regression to examine associations between four survey questions and four socioeconomic factors: country income level, Human Development Index (HDI), health expenditure and physician density.This analysis included 119 MS. MS were more likely to have

Full Text available with Trip Pro

2017 BMC Public Health

16. Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access (PubMed)

Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access The International AIDS Society convened the 3rd International HIV/Viral Hepatitis Co-Infection Meeting on 17 July 2016 as part of the pre-conference program preceding the 21st International AIDS Conference held in Durban, South Africa. The meeting brought together a diversity of scientific, technical and community interests to discuss (...) opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV, particularly in low- and middle-income settings. The objectives of the meeting were:i.To review the latest therapeutic developments in viral hepatitis;ii.To identify challenges such as high cost of medications for hepatitis C virus (HCV) and risk of developing viral resistance, and successes, such as the provision of HCV treatment in community-based settings, movements to reduce drug

Full Text available with Trip Pro

2017 Hepatology, Medicine and Policy

17. The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis (PubMed)

The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis Chimpanzees (Pan troglodytes) have contributed to diverse fields of biomedical research due to their close genetic relationship to humans and in many instances due to the lack of any other animal model. This review focuses on the contributions of the chimpanzee model to research on hepatitis viruses where chimpanzees represented the only animal model (hepatitis B and C (...) ) or the most appropriate animal model (hepatitis A). Research with chimpanzees led to the development of vaccines for HAV and HBV that are used worldwide to protect hundreds of millions from these diseases and, where fully implemented, have provided immunity for entire generations. More recently, chimpanzee research was instrumental in the development of curative therapies for hepatitis C virus infections. Over a span of 40 years, this research would identify the causative agent of NonA,NonB hepatitis

Full Text available with Trip Pro

2017 ILAR Journal

18. Draft resolution: global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, for the period 2016–2021

Draft resolution: global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, for the period 2016–2021 Draft resolution: global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, for the period 2016–2021 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Draft resolution: global health sector strategies on HIV (...) , viral hepatitis and sexually transmitted infections, for the period 2016–2021 View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 69 . (‎2016)‎. Draft resolution: global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, for the period 2016–2021. World Health Organization. Gov't Doc # A69/59 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  Asamblea Mundial de la Salud, 69 (‎ A69/59 , 2016

2016 WHO

19. Draft global health sector strategies. Viral hepatitis, 2016–2021. Report by the Secretariat

Draft global health sector strategies. Viral hepatitis, 2016–2021. Report by the Secretariat Draft global health sector strategies: viral hepatitis, 2016–2021: report by the Secretariat JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Draft global health sector strategies: viral hepatitis, 2016–2021: report by the Secretariat View/ Open View Statistics Altmetrics Share Citation (...) Executive Board, 138 . (‎2016)‎. Draft global health sector strategies: viral hepatitis, 2016–2021: report by the Secretariat. World Health Organization. Gov't Doc # EB138/30 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  Organización Mundial de la Salud (‎ WHO/HIV/2016.06 , 2016 )‎  World Health Organization (‎ WHO/HIV/2016.06 , 2016 )‎  World Health Organization. Regional Office for the Western Pacific (‎ WPR/DCD/HSI(‎06)‎/2014 , 2014 )‎ View

2016 WHO

20. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. (PubMed)

High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. Lipopolysaccharide-binding protein (LBP) has been reported to associate with metabolic diseases, such as obesity, diabetes, and non-alcoholic fatty liver disease. Since chronic hepatitis C virus (HCV) infection is associated with metabolic derangements, the relationship between LBP and HCV deserves additional studies. This study aimed to determine the serum LBP level (...) in subjects with or without HCV infection and investigate the change of its level after anti-viral treatments with or without interferon.We recruited 120 non-HCV subjects, 42 and 17 HCV-infected subjects respectively treated with peginterferon α-2a/ribavirin and direct-acting antiviral drugs. Basic information, clinical data, serum LBP level and abdominal ultrasonography were collected. All the subjects provided written informed consent before being enrolled approved by the Research Ethics Committee

Full Text available with Trip Pro

2017 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>